2Q Revenues: $12.8 billion (-2%)
2Q Earnings: $2.9 billion (-79%)
YTD Revenues: $24.1 billion (-5%)
YTD Earnings: $5.2 billion (-69%)
Comments: Global Vaccines revenue grew 14% operationally, with Prevnar revenue up 13% to $1.1 billion in the quarter. Global Oncology revenues increased 16% to $570 million, primarily driven by the continued strong uptake of Xalkori and Inlyta. Lyrica sales were up 15% to $1.3 billion in the quarter. Viagra sales were down 11% to $427 million. Consumer Healthcare revenues increased 14% to $912 million. Increased generic competition to several products and the end of some revenue-producing partnerships cut revenue by $850 million in the quarter.